| Date |
Title |
|
|
03/17/20
|
Statement from Alkermes on Response to COVID-19
|
|
|
03/04/20
|
Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia
|
|
|
02/24/20
|
Alkermes Response to Media Coverage of the Company and VIVITROL
|
|
|
02/24/20
|
Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 40th Annual Health Care Conference
|
|
|
02/19/20
|
Alkermes to Present at the 9th Annual SVB Leerink Global Healthcare Conference
|
|
|
02/13/20
|
Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020
|
|
|
02/06/20
|
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results
|
|
|
01/28/20
|
Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder
|
|
|
01/08/20
|
Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference
|
|
